首页|冬凌草甲素调节JAK2/STAT3/SOCS-1信号通路对糖耐量异常大鼠胰岛素抵抗的影响

冬凌草甲素调节JAK2/STAT3/SOCS-1信号通路对糖耐量异常大鼠胰岛素抵抗的影响

扫码查看
目的 探讨冬凌草甲素(Oridonin,Ori)对糖耐量异常(impaired glucose tolerance,IGT)大鼠胰岛素抵抗(insulin resistance,IR)的影响及作用机制.方法 采用高脂饮食喂养联合链脲佐菌素注射法构建IGT大鼠IR模型,大鼠分为正常组(CT组)、IGT模型组(IGT组)、Ori组(10 mg·kg-1·d-1)、Ori+Colivelin(COL)组(10 mg·kg-1·d-1 Ori+2 mg/kg COL),每组 6 只.血糖检测仪测定空腹血糖(FPG)、葡萄糖耐量试验(OGTT)2 h血糖(2 hPG),ELISA试剂盒测定空腹胰岛素(FINS)、单核细胞趋化蛋白 1(MCP-1)、肿瘤坏死因子α(TNF-α)含量,计算胰岛素抵抗指数(HOMA-IR),血液自动分析仪测定血清胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)水平,HE 染色观察肝脏病理形态,Western blot 验证附睾脂肪磷酸化(p)-激活 Janus 激活激酶 2(JAK2)、JAK2、p-信号转导和转录激活因子 3(STAT3)、STAT3、p-细胞因子信号传导抑制蛋白 1(SOCS-1)、SOCS-1 蛋白表达.结果 与CT组比较,IGT组大鼠肝脏细胞肿胀,胞浆内可见大量大小不一的脂肪空泡,细胞核被脂肪空泡挤压偏位,且发生炎性细胞浸润,FPG、2hPG、FINS、HOMA-IR、TC、TG、LDL-C、MCP-1、TNF-α 以及 p-JAK2/JAK2、p-STAT3/STAT3、p-SOCS-1/SOCS-1蛋白表达水平升高,血清HDL-C水平下降(P<0.05);与IGT组相比,Ori组大鼠肝脏细胞胞浆内脂肪滴及空泡数量明显减少,细胞肿胀有所缓解,未见炎性细胞浸润,FPG、2hPG、FINS、HOMA-IR、TC、TG、LDL-C、MCP-1、TNF-α以及p-JAK2/JAK2、p-STAT3/STAT3、p-SOCS-1/SOCS-1蛋白表达水平下降,血清HDL-C水平升高(P<0.05);与Ori组相比,Ori+COL组大鼠肝脏脂肪变状况加剧,细胞肿大,血清FPG、2hPG、FINS、HOMA-IR、TC、TG、LDL-C、MCP-1、TNF-α以及p-JAK2/JAK2、p-STAT3/STAT3、p-SOCS-1/SOCS-1 蛋白表达水平升高,血清HDL-C水平下降(P<0.05).结论 Ori对IGT大鼠IR的缓解作用可能与抑制JAK2/STAT3/SOCS-1信号通路激活有关.
Impact of oridonin on insulin resistance in rats with impaired glucose tolerance by regulating the JAK2/STAT3/SOCS-1 signaling pathway
Objective To investigate the impact of oridonin(Ori)on insulin resistance(IR)in rats with impaired glucose tolerance(IGT)and the underlying mechanism.Methods A high-fat diet combined with streptozotocin injection was used to construct an IR model of IGT rats.The rats were grouped into normal group(CT group),IGT model group(IGT group),Ori group(10mg·kg-1·d-1),and Ori+Colivelin(COL)group(10mg·kg-1·d-1 Ori+2mg/kg COL),with 6 rats per group.The fasting blood glucose(FPG)was measured using a glucose meter.The oral glucose tolerance test(OGTT)was performed to test the 2-hour plasma glucose(2hPG).Relative levels of fasting insulin(FINS),monocyte chemotactic protein-1(MCP-1),and tumor necrosis factor-α(TNF-α)were measured by enzyme-linked immunosorbent assay(ELISA).The homeostatic model assessment for insulin resistance(HOMA-IR)was calculated.Serum cholesterol(TC),triglyceride(TG),low-density lipoprotein cholesterol(LDL-C)and high-density lipoprotein cholesterol(HDL-C)were detected using an automatic analyzer.The hematoxylin and eosin(H&E)staining was applied to observe the pathological morphology of the liver.Western blot was applied to detect the protein expressions of phosphorylated Janus kinase 2(p-JAK2),JAK2,phosphorylated signal transducer and activator of transcription 3(p-STAT3),STAT3,phosphorylated suppressor of cytokine signaling 1(p-SOCS-1),and SOCS-1.Results Compared with those of the CT group,rats in IGT group presented swollen liver cells,abundant fat vacuoles of varying sizes in the cytoplasm,squeezing and displacement of nucleus by fat vacuoles,infiltration of inflammatory cells,significantly higher levels of FPG,2hPG,FINS,HOMA-IR,TC,TG,LDL-C,MCP-1,TNF-α,p-JAK2/JAK2,p-STAT3/STAT3 and p-SOCS-1/SOCS-1,and lower serum HDL-C(P<0.05).Compared with those of the IGT group,rats in the Ori group presented significantly fewer fat droplets and vacuoles,alleviated cell swollen,absence of inflammatory cells,significantly lower levels of FPG,2hPG,FINS,HOMA-IR,TC,TG,LDL-C,MCP-1,TNF-α,p-JAK2/JAK2,p-STAT3/STAT3 and p-SOCS-1/SOCS-1,and higher serum HDL-C(P<0.05).Compared with those of Ori group,rats in Ori+COL group presented aggravated liver steatosis,cell swollen,significantly higher levels of FPG,2hPG,FINS,HOMA-IR,TC,TG,LDL-C,MCP-1,TNF-α,p-JAK2/JAK2,p-STAT3/STAT3 and p-SOCS-1/SOCS-1,and lower serum HDL-C(P<0.05).Conclusion Ori alleviates IR in IGT rats by inhibiting the JAK2/STAT3/SOCS-1 signaling pathway.

impaired glucose toleranceinsulin resistanceoridoninJanus activated kinase 2/signal transducer and activator of transcription 3suppressor of cytokine signaling 1

甘志远、陆济华、刘岩、陈汝斌、曾志美

展开 >

530011 广西壮族自治区南宁市妇幼保健院检验科

广西壮族自治区南宁市第八人民医院检验科

糖耐量异常 胰岛素抵抗 冬凌草甲素 Janus激活激酶2 信号转导和转录激活因子3 细胞因子信号传导抑制蛋白1

广西卫生健康委自筹经费科研课题

Z20211472

2024

河北医药
河北省医学情报研究所

河北医药

CSTPCD
影响因子:1.075
ISSN:1002-7386
年,卷(期):2024.46(6)
  • 18